Fibroblast Activation Protein (FAP)

Product List

Creative Biolabs offers extensive anti-FAP-related products to meet your various project requirements.

Background

Fibroblast activation protein (FAP), a type II integral serine protease with dual enzymatic activities, is overexpressed in cancer-associated fibroblasts (CAFs) in various cancer types, including breast cancer, lung malignancy, pancreatic cancer, etc. Several studies have reported that FAP plays a key role in the occurrence, progression, and invasion of tumors. And the overexpression of FAP on CAFs is related to the poor prognosis of multiple tumors. Nowadays, FAP is considered a promising target for tumor therapy.

Fig.1 FAP expression analysis in Pan-cancer.¹

Associated Diseases

• Epithelial cancers
• Breast cancer
• Lung malignancy
• Pancreatic Cancer
• Others

Anti-FAP CAR-T Services

Anti-FAP CAR-T In Vitro Assays

Anti-FAP CAR-T Expression Test

To measure the transduction efficiency of target-specific CART cells, CAR expression detection assays are often used in CART development. Creative Biolabs specializes in providing comprehensive CAR expression assay services to support clients' projects, including but not limited to flow cytometry analysis, WB test, and qPCR analysis.

Fig.2 CAR expression analysis of anti-FAP CART cells by flow cytometry (d) and WB (e).²

Anti-FAP CAR-T Cytokine Release Test

To detect cytokine secretion of CART cells during interaction with targets-expressing tumor cells, Creative Biolabs has developed a variety of optimized assay platforms to suit customers' project needs.

Fig.3 Cytokine secretion analysis (IFN-γ) in FAP-CART cells co-cultured with different target cells at indicated E:T ratio.2

Anti-FAP CAR-T In Vitro Cytotoxicity Assay

The anti-tumor activity verification of CART cells is an important step to test the effectiveness of CART cells. We provide optimized and robust CAR-T cell cytotoxicity testing services to achieve the maximum possible acceleration of the CAR-T project.

Fig.4 In vitrocytotoxicity activity analysis of FAP CAR T-cells against different tumor target cells at indicated E:T ratio.²

Anti-FAP CAR-T In Vivo Assays

Efficacy Test of Anti-FAP CAR-T

For in vivo efficacy tests, Creative Biolabs provides a variety of animal models and in vivo assay services to verify the effectiveness of CAR-T cells to accelerate CART development.

Fig.5 In vivo anti-tumor evaluation of FAP CAR-T in the KPC mice model. A). Tumor growth curve analysis in KPC mice model treated with anti-FAP CAR-T. B). Survival analysis of KPC mice model after the treatment of anti-FAP CAR-T.²

Toxicity Evaluation Anti-FAP CAR-T

There are several difficulties and challenges in CAR-T development, such as off-target effect, CAR-T cell-related toxicity. In order to better detect the relevant reactions in the later stage of CART research and development, we offer various of in vivo assay services for toxicity evaluation and safety assessment ofCAR-T cell therapy, including CRS management, off-target toxicity studies, etc.

In Vivo Model Phenotype Characterization Treated with Anti-FAP CAR-T

To better study the behaviors of target-specific CAR-T cells in vivo, we have developed several phenotype characterization analysis services to meet the diverse needs of our global customers. These services include the following items:

Animal Model Experimental Design

Fig.6 Experimental Scheme of relevant detection in mouse model treated with Anti-FAP CAR-T cells.²

Phenotype Characterization Analysis of Samples from In Vivo Mouse Model Treated with Anti-FAP CAR-T

To evaluate the function of CART cells in vivo, including activation, proliferation, infiltration, exhaustion, etc., Creative Biolabs offers a variety of approaches to test the ability of CART cells.

Ki67 Expression Test

Fig.7 Flow cytometry analysis of Ki67 expression in the model samples after FAP-CAR T cells administration.²

PD-1 Expression Test

Fig.8 Flow cytometry analysis of PD-1 expression in the model samples after FAP-CAR T cells administration.²

Localization Analysis by Multiplex IF

Fig.9 Multiplex IF analysis of FAP-CAR T cells localization in KPC mouse model.²

References

1. Liu, Yifan, et al. "FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18. 2-targeted CAR-T against pancreatic cancer." Journal of Translational Medicine 21.1 (2023): 1-17.
2. Xiao, Zebin, et al. "Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors." Nature Communications 14.1 (2023): 5110.